Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Biogen Idec (BIIB - Analyst Report) recently announced positive top-line data on its phase III multiple sclerosis candidate, peginterferon beta-1a. Results from the ADVANCE study showed that peginterferon beta-1a  met the primary endpoint as well as secondary endpoints.

Detailed Results

Two doses (once in two weeks and once in four weeks) of peginterferon beta-1a were compared to placebo in the study that was conducted to evaluate the safety and efficacy of the candidate in patients suffering from relapsing-remitting multiple sclerosis (RRMS).

Both dosing regimens met the primary endpoint of annualized relapse rate (ARR) at one year. While ARR reduction was 35.6% in the two-week regimen, the four-week regimen saw a 27.5% reduction in ARR.

Secondary endpoints included reduction of the risk of 12-week confirmed disability progression as measured by the Expanded Disability Status Scale (38% for both dosing arms), reduction in the proportion of patients who relapsed (39% the two-week dosing arm and 26% in the four-week dosing arm) and reduction in the number of new or newly enlarging T2-hyperintense lesions on brain MRI scans (67% in the two-week dosing arm and 28% in the four-week dosing arm). Biogen said that safety and tolerability profiles were favorable in both arms.

Biogen intends to present data from this study at the upcoming annual meeting of the American Academy of Neurology (AAN) in March. Meanwhile, with these positive results in hand, the company should be able to go ahead with its plans of filing for US and EU approval this year.

Our Take

We are pleased with Biogen’s progress with its multiple sclerosis (MS) pipeline. A less frequent dosing schedule (not more than 26 doses in a year) and a favorable safety and efficacy profile should work in peginterferon beta-1a’s favor once it is launched.

Biogen is the market leader in therapies for the treatment of multiple sclerosis. We believe the company will continue to retain a leading position in the multiple sclerosis market. Biogen has an important regulatory event coming up with an FDA decision on its oral multiple sclerosis candidate, BG-12, expected in late March. We believe BG-12 could become a leader in the oral multiple sclerosis market once launched. Biogen has another multiple scelrosis candidate, daclizumab, in development with AbbVie (ABBV - Analyst Report).

Biogen currently carries a Zacks #3 Rank (Hold). Biopharma stocks that currently look attractive include companies like Alkermes (ALKS - Analyst Report) and Medivation (MDVN - Analyst Report) – both companies are Zacks Rank #1 (Strong Buy) stocks.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%